The effects of tislelizumab plus chemotherapy as first-line treatment on health-related quality of life of patients with advanced squamous non-small cell lung cancer: Results from a phase 3 randomized clinical trial

Background: This study assessed the effects of adding tislelizumab to first-line standard-of- care chemotherapy on the health-related quality of life (HRQoL) of patients with advanced squamous non-small cell lung cancer (sq-NSCLC). Patients and methods: Patients in this open-label, multicenter, phas...

Cur síos iomlán

Sonraí bibleagrafaíochta

Príomhchruthaitheoirí:	J Wang, X Yu, G Barnes, S Leaw, Y Bao, B Tang
Formáid:	Artigo
Teanga:	Inglês
Foilsithe / Cruthaithe:	Elsevier 2022-01-01
Sraith:	Cancer Treatment and Research Communications
Ábhair:	Squamous non-small cell lung cancer Programmed cell death protein-1 inhibitor Health-related quality of life Patient-reported outcomes Phase 3
Rochtain ar líne:	http://www.sciencedirect.com/science/article/pii/S2468294221001970
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!